Systemic chemotherapy in the treatment of malignant melanoma

Bibliography

• REINTGEN DS, RAPAPORT DP,TANABE KK, ROSS MI: Lymphatic mapping and sentinel lymphadenectomy. In: Cutaneous melanoma. (3'd edn). Balch CM, Houghton AN, Sober AJ, Soong S, (Eds), Quality Medical Publishing, St. Louis, MO, USA (1998):227–244.
   Google Scholar
• AHMED I: Malignant melanoma:prognostic indicators. Mayo Clin. Proc. (1997) 72(4):356–361.
   PubMedGoogle Scholar
• BUZAID AC, ANDERSON CM: The changing prognosis of melanoma. Carr. Oncol Rep. (2000) 2(4):322–328.
   PubMedGoogle Scholar
• ANDERSON CM, BUZAID AC, LEGHA SS: Systemic treatments for advanced cutaneous melanoma. Oncology alentingt) (1995) 9(11):1149–1158.
   PubMedGoogle Scholar
• REID JM, KUFFEL MJ, MILLER JK, RIOS R, AMES MM: Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP 1A1, CYP1A2, and CYP2E1. Clin. Cancer Res. (1999) 5(8):2192–2197.
   PubMed Web of Science ®Google Scholar
• LEE SM, MARGISON GP, THATCHER N, O'CONNOR PJ, COOPER DP: Formation and loss of 06-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br. J. Cancer (1994) 69(5):853–857.
   PubMedGoogle Scholar
• KLIMEK VM, WOLCHOK JD, CHAPMAN PB, HOUGHTON AN, HWU WJ: Systemic chemotherapy. Clin. Plast. Surg. (2000) 27(3):451–61.
   PubMedGoogle Scholar
• BECKER JC, KAMPGEN E,BROCKER E: Classical chemotherapy formetastatic melanoma. Clin. Exp. Dermatol (2000) 25(6):503–508.
   PubMedGoogle Scholar
• NEWBY JC, EISEN T: The role of chemotherapy. In: Melanoma. Critical debates. Newton Bishop JA, Gore M (Eds), Blackwell Science, Oxford, UK (2002):178–194.
   Google Scholar
• MARSH JC: Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatology (1989) 9(5):790–792.
   PubMedGoogle Scholar
• CHAPMAN PB, EINHORN LH, MEYERS ML, SAXMAN S, DESTRO AN, PANAGEAS KS et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.' Clin. Oncol (1999) 17 (9): 2745–2751.
   Google Scholar
• LUIKART SD, KENNEALEY GT, KIRKWOOD JM: Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.Clin. Oncol (1984) 2(3):164–168.
   Google Scholar
• LOPEZ M, PERNO CF, DI LAURO L, PAPALDO P, GANZINA F, BARDUAGNI A: Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest. New Drugs (1984) 2(3):319–322.
   PubMedGoogle Scholar
• SUN W, SCHUCHTER LM: Metastatic melanoma. Can: Treat. Options Oncol (2001) 2(3):193–202.
   PubMedGoogle Scholar
• DANSON SJ, MIDDLETON MR: Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Titer. (2001) 1(1):13–19.
   PubMedGoogle Scholar
• TENTORI L, GRAZIANI G:Pharmacological strategies to increase the antitumor activity of methylating agents. Carr. Med. Chem. (2002) 9(13):1285–1301.
   PubMed Web of Science ®Google Scholar
• BRITTEN CD, ROWINSKY EK, BAKER SD et al: A Phase land pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin. Cancer Res. (1999) 5(7):1629–1637.
   PubMedGoogle Scholar
• YUNG WK: Future directions for temozolomide therapy. Semin. Oncol (2001) 28(4 Suppl. 13):43–6.
   Google Scholar
• AGARWALA SS, KIRKWOOD JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 5(2):144–151.
   PubMedGoogle Scholar
• DOUGLAS JG, MARGOLIN K: The treatment of brain metastases from malignant melanoma. Semin. Oncol (2002) 29(5):518–524.
   PubMedGoogle Scholar
• NEWLANDS ES, BLACKLEDGE GR, SLACK JA et al.: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br: J. Cancer (1992) 65:287–291.
   Google Scholar
• BLEEHEN NM, NEWLANDS ES, LEE SM et al.: Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol (1995) 13:910–913.
   PubMed Web of Science ®Google Scholar
• MIDDLETON M, GROB J,AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol (2000) 18:158–166.
   Google Scholar
• KHAYAT D, GIROUX B, BERILLE J et al.: Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest. (1994) 12(4):414–420.
   PubMed Web of Science ®Google Scholar
• KLEEBERG UR, ENGEL E, ISRAELS P et al.: Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res. (1995) 5(3):195–200.
   Google Scholar
• JACQUILLAT C, KHAYAT D,BANZET P et al: Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.Cancer (1990) 66(9):1873–1878.
   Google Scholar
• KHAYAT D, COUR V, BIZZARI JP et al: Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A Phase II Study. Am. I Clin. Oncol (1991) 14(5):400–404.
   PubMedGoogle Scholar
• LEYVRAZ S, BOSSHARD W,SALMON R et al: Prolonged survival of patients with liver metastases from ocular melanoma: multicentric experience with fotemustine hepatic arterial infusion. Proc. Am. Soc. Clin. Oncol (2002) (Abstract 1360).
   Google Scholar
• AAMDAL S, AVRIL ME GROB JJ et al: A Phase III randomized trial of fotemustine (F) versus dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without brain metastases. Proc. Am. Soc. Clin. Oncol (2002) (Abstract 1361).
   Google Scholar
• LOPES NM, MILLER HP, YOUNG ND, BHUYAN BK: Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays. Cancer Chemothec Pharmacol (1997) 41(1):37–47.
   PubMedGoogle Scholar
• BEDIKIAN AY, WEISS GR, LEGHA SS et al.: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol (1995) 13(12):2895–2899.
   PubMedGoogle Scholar
• AAMDAL S, WOLFF I, KAPLAN S et al: Docetaxel (Taxotere) in advanced malignant melanoma: a Phase II study of the EORTC Early Clinical Trials Group. Eur. I Cancer (1994) 30A(8):1061–1064.
   PubMedGoogle Scholar
• BEDIKIAN AY, PAPADOPOULOS N, PLAGER C, ETON 0, ELLERHORST J, SMITH T: Phase II evaluation of short IV infusion of paclitaxel in metastatic melanoma (M). Proc. Am. Soc. Clin. Oncol (2002) (Abstract 1392).
   Google Scholar
• STEFFENS TA, BAJORIN DF, CHAPMAN PB et al: A Phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.Cancer (1991) 68(6):1230–1237.
   Google Scholar
• TOZER RG, BURDETTE-RADOUX S, BERLANGER K et al: A randomized Phase II study of two schedules of bryostatin-1 (N5C339555) in patients with advanced malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs (2002) 20(4):407–412.
   PubMed Web of Science ®Google Scholar
• GONZALEZ R, EBBINGHAUS S, HENTHORN TK, MILLER D, KRAFT AS: Treatment of patients with metastatic melanoma with bryostatin-l-a Phase II study. Melanoma Res. (1999) 9(6):599–606.
   PubMed Web of Science ®Google Scholar
• DEL PRETE SA, MAURER LH, O'DONNELL J, FORCIER RJ, LEMARBRE P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. (1984) 68(11):1403–1405.
   PubMedGoogle Scholar
• SERRONE L, ZEULI M, SEGA FM, COGNETTI F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. I Exp. Clin. Cancer Res. (2000) 19(1):21–34.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, RING S,PAPADOPOULOS N, PLAGER C, CHAWLA S, BENJAMIN R: A prospective 2210evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 64(10):2024–2029.
   PubMed Web of Science ®Google Scholar
• BUZAID AC, LEGHA SS, WINN R et al: Cisplatin (C), vinblastine (V), dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: Preliminary results of a Phase III Cancer Community Oncology Program (CCOP). Proc. Ann. Meet. Am. Soc. Gin. Oncol. (1993) 12:1328.
   Google Scholar
• ETON 0, LEGHA SS, BEDIKIAN AY et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial.Oncol. (2002) 20(8):2045–2052.
   Google Scholar
• ATZPODIEN J, NEUBER K, KAMANABROU D et al.: Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer (2002) 86 (2) : 179–184.
   Google Scholar
• SEIGLER HF, LUCAS VERSUS JR, PICKETT NJ, HUANG AT: DTIC, CCNU, bleomycin and vincristine (BOLD)in metastatic melanoma. Cancer (1980) 46(11):2346–2348.
   PubMedGoogle Scholar
• YORK RM, FOLTZ AT: Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer (1988) 61(11):2183–2186.
   PubMedGoogle Scholar
• THE PRUDENTE FOUNDATION MELANOMA STUDY GROUP: Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer (1989) 63(9):1676–1680.
   PubMedGoogle Scholar
• PUNT CJ, VAN HERPEN CM, JANSEN RL, VREUGDENHIL G, MULLER EW, DE MULDER PH: Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre Phase II study. Br J. Cancer (1997) 76(2):266–9.
   PubMedGoogle Scholar
• PYRHONEN S,HAHKA-KEMPPINEN M,MUHONEN T et al:Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.Cancer (2002) 95(11):2366–2372.
   Google Scholar
• COSTANZI JJ, FLETCHER WS, BALCERZAK SP et al: Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study. Cancer (1984) 53(4):833–836.
   Google Scholar
• NATIONAL CANCER INSTITUTE OF CANADA MELANOMA GROUP: Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. J. Clin. Oncol. (1984) 2(2):131–134.
   PubMedGoogle Scholar
• LUIKART SD, KENNEALEY GT, KIRKWOOD JM: Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.Oncol. (1984) 2 (3) :164–168.
   Google Scholar